title: Cancer Immunotherapy: Whence and Whither.
abstract: The current concepts and practice of cancer immunotherapy evolved from classical experiments that distinguished "self" from "non-self" and the finding that humoral immunity is complemented by cellular immunity. Elucidation of the biology underlying immune checkpoints and interactions between ligands and ligand receptors that govern the immune system's ability to recognize tumor cells as foreign has led to the emergence of new strategies that mobilize the immune system to reverse this apparent tolerance. Some of these approaches have led to new therapies such as the use of mAbs to interfere with the immune checkpoint. Others have exploited molecular technologies to reengineer a subset of T cells to directly engage and kill tumor cells, particularly those of B-cell malignancies. However, before immunotherapy can become a more effective method of cancer care, there are many challenges that remain to be addressed and hurdles to overcome. Included are manipulation of tumor microenvironment (TME) to enhance T effector cell infiltration and access to the tumor, augmentation of tumor MHC expression for adequate presentation of tumor associated antigens, regulation of cytokines and their potential adverse effects, and reduced risk of secondary malignancies as a consequence of mutations generated by the various forms of genetic engineering of immune cells. Despite these challenges, the future of immunotherapy as a standard anticancer therapy is encouraging.Mol Cancer Res; 15(6); 635-50. ©2017 AACR.
authors.affiliation: Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio. peter.stambrook@uc.edu.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Stambrook
authors.affiliation: Kings College London, CAR Mechanics Group, Guy's Hospital, London, United Kingdom.
authors.forename: John
authors.initials: J
authors.lastname: Maher
authors.affiliation: Division of Cancer Studies, Department of Haematological Medicine, Kings College London, London, United Kingdom.
authors.forename: Farzin
authors.initials: F
authors.lastname: Farzaneh
mesh_terms: D000241:Adenosine / Q000378:metabolism; D016207:Cytokines / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy / Q000009:adverse effects / Q000191:economics / Q000379:methods*; D008285:Major Histocompatibility Complex / Q000276:immunology / Q000502:physiology*; D009154:Mutation; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D059016:Tumor Microenvironment
chemical_list: D016207:Cytokines; D011948:Receptors, Antigen, T-Cell; D000241:Adenosine